Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
American Journal of Nephrology · 2023
DOI: 10.1159/000528783 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Nephrology, 2023. Verfasst von Christian W Mende und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus. Die Arbeit wurde bisher 26-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Diabetic kidney disease (DKD) is a common disorder with multiple serious clinical implications, including an increased risk of end-stage kidney disease (ESKD), cardiovascular complications, heart failure, onset or worsening of hypertension, and premature death. Patients with DKD frequently require dialysis or kidney transplantation to manage their ESKD. Summary: Upregulation of the renin-angiotensin-aldosterone system is an important contributor to kidney disease progression, as highlighted by the results of trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with albuminuria. Increasing evidence suggests the existence of a multidirectional network that involves aldosterone, the mineralocorticoid receptor (MR), and the Ras-related C3 botulinum toxin substrate 1 (Rac1) as driving forces in the generation of reactive oxygen species and oxidative stress-induced injury in the initiation of interstitial nephritis and eventual fibrosis in chronic kidney disease and DKD. The MR is a key element of this triangle, as highlighted by the beneficial effect of MR antagonists in preventing or reducing aldosterone- or Rac1-related effects in basic science studies, and the improved patient outcomes observed in clinical studies. Key Messages: Aldosterone can promote kidney disease in diabetes via the MR and via MR-independent actions through Rac1. However, the MR remains a key element of this triangle, with clinical data supporting the use of MR antagonists in delaying the progression of kidney disease in diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of California San Diego, La Jolla, California, USA.
- Department of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, New York, USA.
Zitieren
APA
Mende, C. W., Samarakoon, R., & Higgins, P. J. (2023). Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists. American Journal of Nephrology. https://doi.org/10.1159/000528783
Vancouver
Mende CW, Samarakoon R, Higgins PJ. Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists. American Journal of Nephrology. 2023. doi:10.1159/000528783
BibTeX
@article{Mende2023,
author = {Mende, Christian W and Samarakoon, Rohan and Higgins, Paul J},
title = {Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists},
journal = {American Journal of Nephrology},
year = {2023},
doi = {10.1159/000528783}
}
EUVIMED